These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28167389)

  • 1. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.
    Zhao Z; Powers K; Hu Y; Raleigh M; Pentel P; Zhang C
    Biomaterials; 2017 Apr; 123():107-117. PubMed ID: 28167389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.
    Zhao Z; Hu Y; Harmon T; Pentel P; Ehrich M; Zhang C
    Biomaterials; 2017 Sep; 138():46-56. PubMed ID: 28551462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.
    Zhao Z; Hu Y; Hoerle R; Devine M; Raleigh M; Pentel P; Zhang C
    Nanomedicine; 2017 Feb; 13(2):443-454. PubMed ID: 27520729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.
    Zhao Z; Harris B; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C
    Biomaterials; 2018 Feb; 155():165-175. PubMed ID: 29179132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.
    Hu Y; Smith D; Frazier E; Hoerle R; Ehrich M; Zhang C
    Biomaterials; 2016 Nov; 106():228-39. PubMed ID: 27569868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins.
    Zhao Z; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C
    Nanomedicine; 2018 Jul; 14(5):1655-1665. PubMed ID: 29719216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradox of PEGylation in fabricating hybrid nanoparticle-based nicotine vaccines.
    Hu Y; Zhao Z; Harmon T; Pentel PR; Ehrich M; Zhang C
    Biomaterials; 2018 Nov; 182():72-81. PubMed ID: 30107271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.
    Le HT; Fraleigh NL; Lewicky JD; Boudreau J; Dolinar P; Bhardwaj N; Diaz-Mitoma F; Montaut S; Fallahi S; Martel AL
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32178357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle.
    Hu Y; Zheng H; Huang W; Zhang C
    Hum Vaccin Immunother; 2014; 10(1):64-72. PubMed ID: 24091786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.
    Laudenbach M; Tucker AM; Runyon SP; Carroll FI; Pravetoni M
    Vaccine; 2015 Nov; 33(46):6332-9. PubMed ID: 26409811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice.
    Pryde DC; Jones LH; Gervais DP; Stead DR; Blakemore DC; Selby MD; Brown AD; Coe JW; Badland M; Beal DM; Glen R; Wharton Y; Miller GJ; White P; Zhang N; Benoit M; Robertson K; Merson JR; Davis HL; McCluskie MJ
    PLoS One; 2013; 8(10):e76557. PubMed ID: 24098532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine.
    Zhao Z; Hu Y; Harmon T; Pentel P; Ehrich M; Zhang C
    Mol Pharm; 2019 Jun; 16(6):2766-2775. PubMed ID: 31075204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates.
    McCluskie MJ; Thorn J; Mehelic PR; Kolhe P; Bhattacharya K; Finneman JI; Stead DR; Piatchek MB; Zhang N; Chikh G; Cartier J; Evans DM; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Apr; 25(2):518-27. PubMed ID: 25737198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.
    Jalah R; Torres OB; Mayorov AV; Li F; Antoline JF; Jacobson AE; Rice KC; Deschamps JR; Beck Z; Alving CR; Matyas GR
    Bioconjug Chem; 2015 Jun; 26(6):1041-53. PubMed ID: 25970207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo.
    Arutla V; Leal J; Liu X; Sokalingam S; Raleigh M; Adaralegbe A; Liu L; Pentel PR; Hecht SM; Chang Y
    ACS Comb Sci; 2017 May; 19(5):286-298. PubMed ID: 28383252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New directions in nicotine vaccine design and use.
    Pentel PR; LeSage MG
    Adv Pharmacol; 2014; 69():553-80. PubMed ID: 24484987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine.
    Hu Y; Smith D; Zhao Z; Harmon T; Pentel PR; Ehrich M; Zhang C
    Nanomedicine; 2019 Aug; 20():102023. PubMed ID: 31181264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like Receptor 9 Agonists as Adjuvants for Nanoparticle-Based Nicotine Vaccine.
    Hu Y; Smith D; Frazier E; Zhao Z; Zhang C
    Mol Pharm; 2021 Mar; 18(3):1293-1304. PubMed ID: 33497574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.
    McCluskie MJ; Pryde DC; Gervais DP; Stead DR; Zhang N; Benoit M; Robertson K; Kim IJ; Tharmanathan T; Merson JR; Davis HL
    Int Immunopharmacol; 2013 May; 16(1):50-6. PubMed ID: 23562759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.